

Special Issue

Vaccines against Influenza Virus

Message from the Guest Editor

Influenza can cause viral pneumonia, especially in the elderly, the chronically ill and the very young, which can lead to breathing difficulties and serious complications. Influenza vaccination is the most effective measure to prevent influenza. However, the understanding of influenza vaccine is far from enough. We are pleased to invite you to contribute this special issue on influence vaccine. The issue aims to discuss the vaccine and related issues, including the epidemic characteristics of influenza under the COVID-19 pandemic, the impact of specific prevention strategies on the epidemic trend, the cross-protection of influenza vaccine, influenza virus variation and control strategies, and the development of new influenza vaccine, etc. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: Epidemiology, clinical trial, Meta-analysis, real world evaluation on influence vaccine. We look forward to receiving your contributions. Dr. Fuqiang Cui

Guest Editor

Prof. Dr. Kevin Coombs

Department of Medical Microbiology, Rady Faculty of Health Sciences,
University of Manitoba, Winnipeg, MB R3E 0J9, Canada

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/114052

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).